← United Therapeutics Corporation (UTHR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
United Therapeutics Corporation (UTHR)
Pharmaceutical Preparations · market cap $21.1B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
20
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
United Therapeutics Corporation (UTHR) is a profitable, cash-generative specialty biopharma focused on pulmonary diseases and organ manufacturing/xenotransplantation, with a $23.5B market cap and ~$1.28B in net cash. The company generated $3.18B in revenue and $1.34B in net income in 2025, anchored by its treprostinil franchise, while advancing a broad pipeline including Phase 3 inhaled treprostinil for progressive pulmonary fibrosis and xenotransplantation programs in ESRD. An earnings catalyst is due July 29, 2026.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-07-01 (est.)Phase 2 · Inhaled Treprostinil (Tyvaso Nebulizer)imp 7/10
- 2027-08-19 (est.)PDUFA · Ralinepagimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Dinutuximab with Chemotherapy | Phase 2 | Neuroblastoma |
| Inhaled Treprostinil | Phase 3 | Progressive Pulmonary Fibrosis |
| UB-421(25 mg/kg) Q2W | Phase 2 | HIV-1 Infection |
| Treprostinil Diolamine | Phase 3 | Pulmonary Arterial Hypertension |
| Ralinepag | Phase 3 | Pulmonary Arterial Hypertension |
| GGTA1 KO Thymokidney | Phase 2 | ESRD (End-Stage Renal Disease) |
| APD811 | Phase 2 | Pulmonary Arterial Hypertension |
| UT-15 | Phase 3 | Pulmonary Hypertension |
| oral treprostinil | Phase 3 | PAH |
| UT-15C SR | Phase 3 | Pulmonary Hypertension |
| ch14.18 -NCI | Phase 2 | Neuroblastoma |
| UT-15C (treprostinil diolamine) | Phase 3 | Pulmonary Arterial Hypertension |
| Dinutuximab | Phase 3 | Small Cell Lung Cancer |
| 10 GE Xenokidney | Phase 2 | ESRD (End-Stage Renal Disease) |
| Oral treprostinil (UT-15C) Sustained Release Tablets | Phase 3 | Pulmonary Hypertension |
| treprostinil diethanolamine | Phase 3 | Pulmonary Arterial Hypertension |
| UT-15C | Phase 2 | Pulmonary Hypertension |
| Tyvaso Inhalation Solution | Phase 2 | Pulmonary Arterial Hypertension |
| UB-421 | Phase 2 | HIV-1 Infection |
| 0.5% Ivermectin lotion | Phase 2 | Pediculosis Capitis |
Price & technical context
3-month
+2.8%
6-month
+0.2%
12-month
+30.4%
52-wk range
$415.34–$596.76
vs 50-day MA
+11.8%
vs 200-day MA
+8.8%
Realized vol
36.3%
Max drawdown
-33.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for UTHR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.